Vertex To Acquire Alpine Immune Sciences for $4.9 Bn
By
Vertex Pharmaceuticals, a Boston-based bio/pharmaceutical company, has agreed to acquire Alpine Immune Sciences, a Seattle, Washington-based clinical-stage bio/pharmaceutical company developing protein-based immunotherapies, for approximately $4.9 billion. Alpine’s lead molecule, povetacicept…